Expanded recall for Franck's Compounds

Share this article:

The FDA is notifying all physicians and healthcare organizations of the recall of all sterile products sold by Franck's Compounding Pharmacy since November 2011 due to the possibility of lack of sterility.

In March 19, 2012, FDA received reports of fungal endophthalmitis in patients who were given Brilliant Blue G (BBG), supplied by Franck's Pharmacy, during eye surgeries. In April 20, 2012, FDA received reports of eye infections in patients who were given injections of Franck's drug products containing triamcinolone acetonide during eye surgery.

An active investigation by the CDC and FDA is ongoing at this time. FDA advises that any product received from Franck's since November 2011 not be used.

For more information visit http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm305592.htm.

Share this article:
You must be a registered member of Clinical Advisor to post a comment.

More in Web Exclusives

DHEA serum levels predict coronary heart disease risk

DHEA serum levels predict coronary heart disease risk

For elderly men, low serum levels of the adrenal sex hormone DHEA and its sulfate, DHEA-S, predict coronary heart disease risk.

Prenatal exposure to sodium valproate linked to lower IQ in offspring

Prenatal exposure to sodium valproate linked to lower ...

The IQ of children exposed to VPA was lower compared with children born to women without epilepsy and that of those exposed to carbamazepine.

FDA approves first Meningococcal B vaccine

FDA approves first Meningococcal B vaccine

The FDA has approved Trumenba, the first vaccine approved in the U.S. to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B